Digene
This article was originally published in The Gray Sheet
Executive Summary
Preliminary clinical trial results show that the firm's human papillomavirus (HPV) cervical cancer screening diagnostic detected "approximately 90% of cervical cancer precursors" compared to the approximately 67% detected by Pap smears, the company announces Jan. 15. Based on 23,000 women in seven countries, the study also found the sensitivity of the HPV screen to range from 81-97% compared to the 37-84% sensitivity range for Pap smears
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.